Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gain Therapeutics (GANX) Cash from Operations (2020 - 2025)

Historic Cash from Operations for Gain Therapeutics (GANX) over the last 6 years, with Q3 2025 value amounting to -$4.9 million.

  • Gain Therapeutics' Cash from Operations rose 1892.25% to -$4.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$17.3 million, marking a year-over-year increase of 1792.25%. This contributed to the annual value of -$18.9 million for FY2024, which is 4.22% down from last year.
  • Latest data reveals that Gain Therapeutics reported Cash from Operations of -$4.9 million as of Q3 2025, which was up 1892.25% from -$5.1 million recorded in Q2 2025.
  • Over the past 5 years, Gain Therapeutics' Cash from Operations peaked at -$2.2 million during Q3 2021, and registered a low of -$6.1 million during Q3 2024.
  • Moreover, its 5-year median value for Cash from Operations was -$4.0 million (2023), whereas its average is -$4.1 million.
  • In the last 5 years, Gain Therapeutics' Cash from Operations plummeted by 65840.79% in 2021 and then surged by 3896.81% in 2024.
  • Over the past 5 years, Gain Therapeutics' Cash from Operations (Quarter) stood at -$4.1 million in 2021, then rose by 5.83% to -$3.9 million in 2022, then crashed by 44.97% to -$5.7 million in 2023, then surged by 38.97% to -$3.5 million in 2024, then plummeted by 42.6% to -$4.9 million in 2025.
  • Its Cash from Operations stands at -$4.9 million for Q3 2025, versus -$5.1 million for Q2 2025 and -$3.8 million for Q1 2025.